Pricing
  1. US-listed companies
  2. KYNTRA BIO, INC.
  3. Financials
  4. Stockholders' equity

KYNTRA BIO, INC.【KYNB】

Market cap
$28.19M
P/E ratio
SummaryFinancials
Period EndStockholders' equity (Million USD)YoY (%)
Dec 31, 2024-205+11.67%
Dec 31, 2023-184+12310.74%
Dec 31, 2022-1-100.65%
Dec 31, 2021229-48.10%
Dec 31, 2020441-17.55%
Dec 31, 2019535+1.31%
Dec 31, 2018528-9.27%
Dec 31, 2017582+232.62%
Dec 31, 2016175-11.03%
Dec 31, 2015197

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)